11:31 , Jun 10, 2019 |  BioCentury  |  Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

Oncologie's strategy of pairing in-licensed, later-stage compounds with biomarkers led Nan Fung Life Sciences and Pivotal bioVenture Partners China to return to invest in the cancer company's tranched $80 million series B. The funds are...
16:46 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures also joined the round. Oncologie...
21:33 , Jun 7, 2018 |  BC Extra  |  Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures also joined the round. Oncologie...
20:27 , Feb 23, 2018 |  BC Week In Review  |  Financial News

Avid raises $23M in follow-on

Contract development and manufacturing company Avid Bioservices Inc. (NASDAQ:CDMO) raised $23.2 million through the sale of 10.3 million shares at $2.25 in a follow-on underwritten by Wells Fargo, H.C. Wainwright and Roth. The figures include...
20:00 , Feb 16, 2018 |  BC Week In Review  |  Company News

Oncologie purchases bavituximab from Avid

Oncologie Ltd. (Cayman Islands) acquired a phosphatidylserine-targeting program including bavituximab from Avid Bioservices Inc. (NASDAQ:CDMO), formerly Peregrine Pharmaceuticals. Avid, which transitioned to a contract development and manufacturing organization in January, will receive $8 million upfront...
00:14 , Dec 28, 2017 |  BC Extra  |  Company News

Management tracks: Vivus, Peregrine

Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) said CEO Seth Fischer will step down. Thomas King, a director, will serve as interim CEO as the company seeks a permanent replacement. King was president and...
23:02 , Dec 22, 2017 |  BC Extra  |  Company News

Management tracks: CRISPR, Hua

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) appointed Rodger Novak as chairman of the board. He succeeds Tony Coles, who will remain as a senior adviser. Novak is founder and president of CRISPR, and served...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Bavituximab: Interim Phase III data

Interim data from the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC showed that once-weekly IV bavituximab plus docetaxel missed the primary endpoint of improving median...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Bavituximab: Phase III discontinued

Peregrine discontinued the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC after a pre-specified interim analysis by an IDMC showed that once-weekly IV bavituximab plus docetaxel...